Purple Biotech Price To Sales vs. Total Debt
| PPBT Stock | USD 4.21 0.10 2.43% |
Purple Biotech Price To Sales Ratio |
|
For Purple Biotech profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Purple Biotech to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Purple Biotech utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Purple Biotech's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Purple Biotech over time as well as its relative position and ranking within its peers.
Purple |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Purple Biotech. If investors know Purple will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Purple Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 81 | Return On Assets (0.29) | Return On Equity (0.45) |
The market value of Purple Biotech is measured differently than its book value, which is the value of Purple that is recorded on the company's balance sheet. Investors also form their own opinion of Purple Biotech's value that differs from its market value or its book value, called intrinsic value, which is Purple Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Purple Biotech's market value can be influenced by many factors that don't directly affect Purple Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Purple Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Purple Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Purple Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Purple Biotech Total Debt vs. Price To Sales Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Purple Biotech's current stock value. Our valuation model uses many indicators to compare Purple Biotech value to that of its competitors to determine the firm's financial worth. Purple Biotech is rated below average in price to sales category among its peers. It is rated below average in total debt category among its peers making up about 6,044 of Total Debt per Price To Sales. At this time, Purple Biotech's Price To Sales Ratio is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Purple Biotech by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Purple Total Debt vs. Price To Sales
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Purple Biotech |
| = | 58.08 X |
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Purple Biotech |
| = | 351 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Purple Total Debt vs Competition
Purple Biotech is rated below average in total debt category among its peers. Total debt of Health Care industry is at this time estimated at about 88.36 Million. Purple Biotech adds roughly 351,000 in total debt claiming only tiny portion of equities under Health Care industry.
Purple Biotech Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Purple Biotech, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Purple Biotech will eventually generate negative long term returns. The profitability progress is the general direction of Purple Biotech's change in net profit over the period of time. It can combine multiple indicators of Purple Biotech, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 38.5 M | 40.4 M | |
| Operating Income | 22.3 M | 23.4 M | |
| Income Before Tax | -20 M | -19 M | |
| Total Other Income Expense Net | -42.2 M | -40.1 M | |
| Net Loss | -19.9 M | -18.9 M | |
| Income Tax Expense | -97 K | -101.8 K | |
| Net Interest Income | -1.7 M | -1.6 M | |
| Interest Income | 474 K | 344.4 K | |
| Net Loss | -20 M | -21 M | |
| Net Loss | -19.5 M | -20.5 M | |
| Change To Netincome | 1.7 M | 1.6 M | |
| Income Quality | 1.00 | 0.62 |
Purple Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Purple Biotech. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Purple Biotech position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Purple Biotech's important profitability drivers and their relationship over time.
Use Purple Biotech in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Purple Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Purple Biotech will appreciate offsetting losses from the drop in the long position's value.Purple Biotech Pair Trading
Purple Biotech Pair Trading Analysis
The ability to find closely correlated positions to Purple Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Purple Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Purple Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Purple Biotech to buy it.
The correlation of Purple Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Purple Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Purple Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Purple Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Purple Biotech position
In addition to having Purple Biotech in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Drugs Thematic Idea Now
Drugs
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Purple Stock Analysis
When running Purple Biotech's price analysis, check to measure Purple Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Purple Biotech is operating at the current time. Most of Purple Biotech's value examination focuses on studying past and present price action to predict the probability of Purple Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Purple Biotech's price. Additionally, you may evaluate how the addition of Purple Biotech to your portfolios can decrease your overall portfolio volatility.